European listed biotech companies: stock performance tracking after the coronavirus outbreak (updated)

The markets have been very volatile lately, and the main indices have known historical sessions in terns or performances on last Monday (09/03/2020), and even worse on last Thursday (12/03/2020, a real “Black Thursday” of the 21st century). That day, the European markets saw either their largest falls ever, either their worst performances since 19/10/1987[…]

European listed biotech landscape: 2019 review and outlook for 2020

2018 was a very bad year for the European biotech landscape, so the question was whether a rebound coud take place or not in 2019, in a global environment where the recurring macro themes basically remained unchanged: US/China trade war, Brexit, rates, recession fears (you know, the one that is announced every year for the[…]

Deal Monitor: status at the end of Q3 2019

It’s time to make a top view status of the deal activity for the 150+ European listed biotech companies in our universe. The data below include deals from all categories (R&D collaborations, Out-Licensing deals, Supply/Distribution deals, JV, IP licensing, Sales/Divestments), except the in-licensing deals. Please refer to our introductory report for more details and explanations.[…]

We Are Now Open!

Dear all, this is my great pleasure to announce the launch of biotechradar.eu today. This is a subscription service for pro-investors and profressionals in Life Sciences, providing data and intel on the European landscape of public biotech companies. Pipeline data and financials are obviously the backbones of the service, but there’s indeed more. The underlying[…]